Takeda continues non-core asset sell-off for $825M

Takeda Pharmaceuticals continues to combat its Shire acquisition-related debt by selling off another set of non-core assets to Hypera in Brazil, the company announced March 2.

Advertisement

What you should know:

1. Hypera gave the Japanese drugmaker $825 million for a number of over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru.

2. Takeda has completed five similar transactions recently. The company aims to divest $10 billion of its non-core assets to pay off its debt.

3. After acquiring Shire in January 2019, Takeda became one of the largest and most indebted drugmakers in the world.

More articles on surgery centers:
PE-backed Prism Vision snags Maryland eye group — 4 insights
Florida ASC buyer projects $18M profit in 1st year: 5 details
Physician-owned eye group acquires California practice 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.